Strategic partnerships Inhalation Sciences Sweden AB has recently partnered with Actarmo Medical GmbH to offer end-to-end inhalation product development services from preclinical stages to clinical trial supplies, presenting a joint sales opportunity to co-market integrated capabilities.

Precision platform The proprietary PreciseInhale technology enables precise aerosol dosing, high quality pharmacokinetic data, and improved clinical predictability, suggesting upsell opportunities to clients seeking faster, de-risked inhalation programs with potential for reduced API use and animal testing.

Clinical readiness With a focus on IND, generics, and biologics development and a track record of de-risking inhaled programs, target mid- to late-stage biotech and pharma companies aiming to advance inhaled therapies efficiently and confidently.

Expert leadership Founder and CSO Per Gerde is a recognized authority in inhalation toxicology, enabling credible engagement with potential customers seeking validated scientific leadership and deep domain expertise for complex inhalation projects.

Growth signals Recent news and the launch of PreciseInhale in 2021, coupled with Q4 2023 reporting and ongoing collaboration history, indicate a growth trajectory that can be leveraged to position IS Sweden as a scalable CRO partner for inhalation drug development in Europe.